{Reference Type}: Journal Article
{Title}: Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review.
{Author}: Hussaini SA;Waziri B;Dickens C;Duarte R;
{Journal}: Pharmacogenomics
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 7
{Factor}: 2.638
{DOI}: 10.1080/14622416.2024.2370761
{Abstract}: Calcineurin inhibitors (CNIs) are the mainstay of immunosuppression in kidney transplantation. Interpatient variability in the disposition of calcineurin inhibitors is a well-researched phenomenon and has a well-established genetic contribution. There is great diversity in the makeup of African genomes, but very little is known about the pharmacogenetics of CNIs and transplant outcomes. This review focuses on genetic variants of calcineurin inhibitors' metabolizing enzymes (CYP3A4, CYP3A5), related molecules (POR, PPARA) and membrane transporters involved in the metabolism of calcineurin inhibitors. Given the genetic diversity across the African continent, it is imperative to generate pharmacogenetic data, especially in the era of personalized medicine and emphasizes the need for studies specific to African populations. The study of allelic variants in populations where they have greater frequencies will help answer questions regarding their impact. We aim to fill the knowledge gaps by reviewing existing research and highlighting areas where African research can contribute.<BR>Research on the pharmacogenetics of calcineurin inhibitors in kidney transplant recipients is truly wanting in data from the African continent. Given Africa's vast genetic diversity, it is necessary to intensify efforts to generate data from Africa in this field.